Literature DB >> 8875204

Automated reasoning system in histopathologic diagnosis and prognosis of prostate cancer and its precursors.

P H Bartels1, D Thompson, R Montironi, G Mariuzzi, P W Hamilton.   

Abstract

OBJECTIVE: This article presents the rationale and options offered to diagnostic and prognostic decision support systems for prostate pathology by automated reasoning capabilities.
METHODS: The symbolic information used in diagnostic decision-making is systematically ordered, compared, numerically assessed in its probability, and combined such that a conclusion can be drawn. The framework for the processing of such symbolic information may be an expert system, an inference network or a case-based reasoning system. Automated reasoning is implemented by the use of a rule base and information flow control modules.
RESULTS: Automated reasoning allows decision support systems to follow highly adaptive decision sequences, capable of handling contradictory evidence, exceptions in diagnostic clue expression, and nonmonotonic decision-making.
CONCLUSIONS: Automated reasoning capability in diagnostic and prognostic decision support systems allows highly flexible decision development, very close to human decision procedures.

Entities:  

Mesh:

Year:  1996        PMID: 8875204     DOI: 10.1159/000474173

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  3 in total

Review 1.  Precursor lesions for prostate cancer.

Authors:  M R Feneley; C Busch
Journal:  J R Soc Med       Date:  1997-10       Impact factor: 5.344

2.  Diagnostic distance of high grade prostatic intraepithelial neoplasia from normal prostate and adenocarcinoma.

Authors:  R Montironi; R Pomante; P Colanzi; D Thompson; P W Hamilton; P H Bartels
Journal:  J Clin Pathol       Date:  1997-09       Impact factor: 3.411

3.  Using MATLAB software with Tomcat server and Java platform for remote image analysis in pathology.

Authors:  Tomasz Markiewicz
Journal:  Diagn Pathol       Date:  2011-03-30       Impact factor: 2.644

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.